The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

(2018) Naoise C. Synnott et al.   CANCER LETTERS

CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion

(2017) Jerry F. Tien et al.   NUCLEIC ACIDS RESEARCH

Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma

(2017) Zheling Chen et al.   PLoS One

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

(2017) Sonja Thaler et al.   Oncotarget

ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis

(2016) Mei Xu et al.   Molecular Cancer

Recent perspectives of breast cancer prognosis and predictive factors

(2016) Su-Sheng Cao et al.   Oncology Letters

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells

(2015) Zhike Chen et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Palbociclib for hormone receptor-positive breast cancer

(2015) Emilia Harding   LANCET ONCOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

(2012) Rita Nahta et al.   BREAST CANCER RESEARCH AND TREATMENT

Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab

(2012) Mary Kay Barton   CA-A CANCER JOURNAL FOR CLINICIANS

Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells

(2012) J. Cui et al.   CANCER RESEARCH

Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance

(2012) Rocío García-Becerra et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer

(2010) J J Frietsch et al.   BRITISH JOURNAL OF CANCER

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

(2008) Da Wei Huang et al.   NUCLEIC ACIDS RESEARCH

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY